| A Study of LY4257496 in Participants With Cancer (OMNIRAY) (NCT07114601) | Eli Lilly and Company | 2025-08-06 |
| A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (NCT07100119) | Eli Lilly and Company | 2025-08-05 |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia (NCT06721013) | Eli Lilly and Company | 2025-07-30 |
| A Study of LY4175408 in Participants With Advanced Cancer (NCT07046923) | Eli Lilly and Company | 2025-07-28 |
| A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus (NCT07073170) | Eli Lilly and Company | 2025-07-25 |
| A Study of LY4088044 in Healthy Participants (NCT07090785) | Eli Lilly and Company | 2025-07-24 |
| A Study of LY3549492 in Healthy Weight Adult Participants (NCT07085468) | Eli Lilly and Company | 2025-07-21 |
| A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (NCT07044271) | Eli Lilly and Company | 2025-07-11 |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (NCT06937099) | Eli Lilly and Company | 2025-06-26 |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (NCT06937086) | Eli Lilly and Company | 2025-06-26 |
| A Study of Remternetug (LY3372993) in Healthy Participants (NCT07056309) | Eli Lilly and Company | 2025-06-24 |
| A Study of [14C]-LY4065967 in Healthy Participants (NCT07039045) | Eli Lilly and Company | 2025-06-23 |
| A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes (NCT07030868) | Eli Lilly and Company | 2025-06-19 |
| A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (NCT07006792) | Eli Lilly and Company | 2025-06-16 |
| A Study of LY3981314 in Healthy Participants (NCT07005284) | Eli Lilly and Company | 2025-06-09 |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia (NCT06982846) | Eli Lilly and Company | 2025-06-06 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus (NCT06982859) | Eli Lilly and Company | 2025-06-02 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (NCT07035093) | Eli Lilly and Company | 2025-05-29 |
| A Study of LY3867070 in Healthy Participants (NCT07021547) | Eli Lilly and Company | 2025-05-27 |
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes (NCT06901349) | Eli Lilly and Company | 2025-05-23 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma (NCT06876662) | Eli Lilly and Company | 2025-05-20 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib (NCT06876649) | Eli Lilly and Company | 2025-05-20 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes (NCT06972472) | Eli Lilly and Company | 2025-05-19 |
| A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (NCT06945406) | Eli Lilly and Company | 2025-05-16 |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes (NCT06993792) | Eli Lilly and Company | 2025-05-15 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity (NCT06972459) | Eli Lilly and Company | 2025-05-15 |
| A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants (NCT07046559) | Eli Lilly and Company | 2025-05-13 |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (NCT06962280) | Eli Lilly and Company | 2025-05-12 |
| A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants (NCT06869018) | Eli Lilly and Company | 2025-05-07 |
| A Study of LY4268989 (MORF-057) in Healthy Participants (NCT06964776) | Eli Lilly and Company | 2025-05-01 |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) (NCT06948422) | Eli Lilly and Company | 2025-04-30 |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 (NCT06948435) | Eli Lilly and Company | 2025-04-30 |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 (NCT06952530) | Eli Lilly and Company | 2025-04-30 |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (NCT06914895) | Eli Lilly and Company | 2025-04-25 |
| A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes (NCT06945419) | Eli Lilly and Company | 2025-04-23 |
| A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function (NCT06916078) | Eli Lilly and Company | 2025-04-23 |
| A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (NCT06921759) | Eli Lilly and Company | 2025-04-21 |
| A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (NCT06916091) | Eli Lilly and Company | 2025-04-21 |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (NCT06916065) | Eli Lilly and Company | 2025-04-09 |
| Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid (NCT06916143) | Eli Lilly and Company | 2025-04-08 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide (NCT06897475) | Eli Lilly and Company | 2025-03-28 |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (NCT06890598) | Eli Lilly and Company | 2025-03-27 |
| A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants (NCT06890611) | Eli Lilly and Company | 2025-03-25 |
| A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis (NCT06859294) | Eli Lilly and Company | 2025-03-19 |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) (NCT06857942) | Eli Lilly and Company | 2025-03-19 |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) (NCT06864026) | Eli Lilly and Company | 2025-03-06 |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (NCT06859268) | Eli Lilly and Company | 2025-03-05 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight (NCT06824051) | Eli Lilly and Company | 2025-02-17 |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (NCT06817356) | Eli Lilly and Company | 2025-02-06 |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants (NCT06808802) | Eli Lilly and Company | 2025-02-03 |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) (NCT06739122) | Eli Lilly and Company | 2025-01-10 |
| A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants (NCT06692348) | Eli Lilly and Company | 2024-12-13 |
| A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants (NCT06719128) | Eli Lilly and Company | 2024-12-06 |
| A Study of LY4060874 in Healthy Participants (NCT06709820) | Eli Lilly and Company | 2024-12-02 |
| A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) (NCT06672549) | Eli Lilly and Company | 2024-11-18 |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities (NCT06672939) | Eli Lilly and Company | 2024-11-18 |
| A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight (NCT06683508) | Eli Lilly and Company | 2024-11-13 |
| A Study of LY4005130 in Healthy Participants (NCT06690996) | Eli Lilly and Company | 2024-11-08 |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (NCT06662383) | Eli Lilly and Company | 2024-11-01 |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) (NCT06657768) | Eli Lilly and Company | 2024-10-29 |
| A Study of [14C]-LY3866288 in Healthy Participants (NCT06644378) | Eli Lilly and Company | 2024-10-28 |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy (NCT06413706) | Eli Lilly and Company | 2024-10-25 |
| A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (NCT06649045) | Eli Lilly and Company | 2024-10-22 |
| A Study of LY4065967 in Healthy Japanese Participants (NCT06594159) | Eli Lilly and Company | 2024-10-22 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight (NCT06643728) | Eli Lilly and Company | 2024-10-21 |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (NCT06607185) | Eli Lilly and Company | 2024-10-21 |
| A Study of LY3866288 in Healthy Participants (NCT06641037) | Eli Lilly and Company | 2024-10-17 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan (NCT06635057) | Eli Lilly and Company | 2024-10-11 |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (NCT06598943) | Eli Lilly and Company | 2024-10-10 |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus (NCT06362265) | Eli Lilly and Company | 2024-10-10 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (NCT06588283) | Eli Lilly and Company | 2024-09-30 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (NCT06588296) | Eli Lilly and Company | 2024-09-24 |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (NCT06603571) | Eli Lilly and Company | 2024-09-20 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (NCT06561685) | Eli Lilly and Company | 2024-09-19 |
| A Study of LY3537031 in Overweight, Obese, and Healthy Participants (NCT06606106) | Eli Lilly and Company | 2024-09-05 |
| A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease (NCT06538116) | Eli Lilly and Company | 2024-08-26 |
| Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy (NCT06568042) | Eli Lilly and Company | 2024-08-22 |
| A Study of LY3532226 in Participants With Obesity (NCT06557356) | Eli Lilly and Company | 2024-08-16 |
| A Study of Subcutaneous Injection in Healthy Participants (NCT06516913) | Eli Lilly and Company | 2024-07-22 |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NCT06465069) | Eli Lilly and Company | 2024-07-01 |
| A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980) | Eli Lilly and Company | 2024-06-24 |
| A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants (NCT06475729) | Eli Lilly and Company | 2024-06-24 |
| A First-In-Human Study of LY3985297 in Healthy Participants (NCT06395012) | Eli Lilly and Company | 2024-06-07 |
| Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis (NCT06444165) | Eli Lilly and Company | 2024-06-04 |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) (NCT06439277) | Eli Lilly and Company | 2024-06-03 |
| A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (NCT06400472) | Eli Lilly and Company | 2024-05-20 |
| A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (NCT06280703) | Eli Lilly and Company | 2024-05-15 |
| A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants (NCT06370728) | Eli Lilly and Company | 2024-05-06 |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (NCT06383390) | Eli Lilly and Company | 2024-04-30 |
| A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (NCT06338995) | Eli Lilly and Company | 2024-04-29 |
| A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (NCT06339008) | Eli Lilly and Company | 2024-04-26 |
| A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity (NCT06373146) | Eli Lilly and Company | 2024-04-24 |
| A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (NCT06370715) | Eli Lilly and Company | 2024-04-18 |
| A Study of LY3841136 in Japanese Participants With Obesity or Overweight (NCT06297616) | Eli Lilly and Company | 2024-04-15 |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) (NCT06354660) | Eli Lilly and Company | 2024-04-10 |
| [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (NCT06229366) | Eli Lilly and Company | 2024-04-03 |
| A Study of LY3841136 in Overweight and Obese Participants (NCT06345066) | Eli Lilly and Company | 2024-04-03 |
| A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants (NCT06243198) | Eli Lilly and Company | 2024-03-28 |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 (NCT06313528) | Eli Lilly and Company | 2024-03-20 |
| A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis (NCT06220669) | Eli Lilly and Company | 2024-03-19 |